Brokerages Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Target Price at $48.00

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been given an average rating of “Moderate Buy” by the twelve brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $48.00.

A number of analysts have recently issued reports on NAMS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Guggenheim raised their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Stifel Nicolaus lifted their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Royal Bank Of Canada boosted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Finally, HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th.

NewAmsterdam Pharma Trading Up 3.7%

Shares of NewAmsterdam Pharma stock opened at $30.01 on Friday. The business’s fifty day moving average price is $32.57 and its 200 day moving average price is $33.69. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $42.00. The stock has a market capitalization of $3.45 billion, a P/E ratio of -17.35 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. As a group, sell-side analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Buying and Selling

In other news, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $30.29, for a total value of $3,071,678.61. Following the completion of the sale, the insider owned 69,302 shares of the company’s stock, valued at $2,099,157.58. This represents a 59.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the sale, the chief executive officer owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 1,391,816 shares of company stock valued at $45,728,031. Company insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $140,000. Empowered Funds LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth $85,000. XTX Topco Ltd lifted its position in shares of NewAmsterdam Pharma by 1,714.1% during the fourth quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock worth $4,823,000 after purchasing an additional 129,913 shares in the last quarter. Virtus Investment Advisers LLC boosted its stake in shares of NewAmsterdam Pharma by 32.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock valued at $251,000 after purchasing an additional 1,731 shares during the period. Finally, Twinbeech Capital LP purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at $961,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.